220 related articles for article (PubMed ID: 29966452)
1. Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
Melesina J; Praetorius L; Simoben CV; Robaa D; Sippl W
Future Med Chem; 2018 Jul; 10(13):1537-1540. PubMed ID: 29966452
[TBL] [Abstract][Full Text] [Related]
2. Strategies To Design Selective Histone Deacetylase Inhibitors.
Melesina J; Simoben CV; Praetorius L; Bülbül EF; Robaa D; Sippl W
ChemMedChem; 2021 May; 16(9):1336-1359. PubMed ID: 33428327
[TBL] [Abstract][Full Text] [Related]
3. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
4. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
5. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
6. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
[TBL] [Abstract][Full Text] [Related]
8. Towards isozyme-selective HDAC inhibitors for interrogating disease.
Gupta P; Reid RC; Iyer A; Sweet MJ; Fairlie DP
Curr Top Med Chem; 2012; 12(14):1479-99. PubMed ID: 22827519
[TBL] [Abstract][Full Text] [Related]
9. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
[TBL] [Abstract][Full Text] [Related]
10. Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.
Zhu Y; Li HF; Lu S; Zheng YX; Wu Z; Tang WF; Zhou X; Lu T
Eur J Med Chem; 2010 May; 45(5):1777-91. PubMed ID: 20153566
[TBL] [Abstract][Full Text] [Related]
11. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
Kalyaanamoorthy S; Chen YP
Biochim Biophys Acta; 2013 Jan; 1834(1):317-28. PubMed ID: 23457710
[TBL] [Abstract][Full Text] [Related]
12. Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes.
Kandasamy S; Selvaraj M; Muthusamy K; Varadaraju N; Kannupal S; Sekar AK; Vilwanathan R
J Biomol Struct Dyn; 2023 Mar; 41(5):1690-1703. PubMed ID: 34994284
[TBL] [Abstract][Full Text] [Related]
13. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
14. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
16. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
Hou X; Du J; Liu R; Zhou Y; Li M; Xu W; Fang H
J Chem Inf Model; 2015 Apr; 55(4):861-71. PubMed ID: 25757142
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.
Terracciano S; Chini MG; Riccio R; Bruno I; Bifulco G
ChemMedChem; 2012 Apr; 7(4):694-702. PubMed ID: 22278987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
